Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder

Psychoneuroendocrinology

Volumn 35, Issue 7, 2010, Pages 1001-1007

  Strawn, Jeffrey R ^a,c,f   Pyne Geithman, Gail J ^a   Ekhator, Nosakhare N ^a,c   Horn, Paul S ^b,c   Uhde, Thomas W ^g   Shutter, Lori A ^a   Baker, Dewleen G ^d,e   Geracioti, Thomas D ^a,c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cerebrospinal fluid (CSF); Hypocretin; Hypothalamic pituitary adrenal axis (HPA axis); Orexin; Posttraumatic stress disorder (PTSD); Trauma

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; DOPAMINE; HOMOVANILLIC ACID; OREXIN A;

ADULT; ANXIETY DISORDER; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; MALE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEPLETION; PROTEIN DETERMINATION; SEROTONINERGIC SYSTEM; SYMPTOM; VETERAN;

ADULT; COMBAT DISORDERS; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEUROPEPTIDES; STRESS DISORDERS, POST-TRAUMATIC; VETERANS; YOUNG ADULT;

EID: 77954956414     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2010.01.001     Document Type: Article

References (47)

1. Al-Barazanji K.A., Wilson S., Baker J., Jessop D.S., Harbuz M.S. Central orexin-A activates hypothalamic-pituitary-adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats. J. Neuroendocrinol. 2001, 13:421-424.
2. Avrameas S. Amplification systems in immunoenzymatic techniques. J. Immunol. Methods 1992, 150:23-32.
3. Baker D.G., West S.A., Nicholson W.E., Ekhator N.N., Kasckow J.W., Hill K.K., Bruce A.B., Orth D.N., Geracioti T.D. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am. J. Psychiatry 1999, 156:585-588.
4. Blake D.D., Weathers F.W., Nagy L.M., Kaloupek D.G., Gusman F.D., Charney D.S., Keane T.M. The development of a Clinician-Administered PTSD scale. J. Trauma. Stress 1995, 8:75-90.
5. Blanco M., López M., GarcIa-Caballero T., Gallego R., Vázquez-Boquete A., Morel G., SeñarIs R., Casanueva F., Diéguez C., Beiras A. Cellular localization of orexin receptors in human pituitary. J. Clin. Endocrinol. Metab. 2001, 86:1616-1619.
6. Bremner J.D., Licinio J., Darnell A., Krystal J.H., Owens M.J., Southwick S.M., Nemeroff C.B., Charney D.S. Elevated CSF corticotrophin-releasing factor concentrations in posttraumatic stress disorder. Am. J. Psychiatry 1997, 54:624-629.
7. Brundin L., Björkqvist M., Petersén A., Träskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur. Neuropsychopharmacol. 2007, 17:573-579.
8. Brundin L., Petersén A., Björkqvist M., Träskman-Bendz L. Orexin and psychiatric symptoms in suicide attempters. J. Affect. Disord. 2007, 100:259-263.
9. Brunton P.J., Russell J.A. Hypothalamic-pituitary-adrenal responses to centrally administered orexin-A are suppressed in pregnant rats. J. Neuroendocrinol. 2003, 15:633-637.
10. Bubser M., Fadel J.R., Jackson L.L., Meador-Woodruff J.H., Jing D., Deutch A.Y. Dopaminergic regulation of orexin neurons. Eur. J. Neurosci. 2005, 21:2993-3001.
11. Bucht E., Granberg B., Sjostedt U., Torring O. A rapid extraction method for serum calcitonin. Clin. Chim. Acta 1991, 195:115-124.
12. Chudakov B., Cohen H., Matar M.A., Kaplan Z. A naturalistic prospective open study of the effects of adjunctive therapy of sexual dysfunction in chronic PTSD patients. Isr. J. Psychiatry Relat. Sci. 2008, 45:26-32.
13. Cosgrove D.J., Gordon Z., Bernie J.E., Hami S., Montoya D., Stein M.B., Monga M. Sexual dysfunction in combat veterans with post-traumatic stress disorder. Urology 2002, 60:881-884.
14. Dalal M.A., Schuld A., Pollmächer T. Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects. Mol. Psychiatry 2003, 8:836-837.
15. de Lecea L., Kilduff T.S., Peyron C., Gao X., Foye P.E., Danielson P.E., Fukuhara C., Battenberg E.L., Gautvik V.T., Bartlett F.S., Frankel W.N., van den Pol A.N., Bloom F.E., Gautvik K.M., Sutcliffe J.G. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:322-327.
16. Feng P., Vurbic D., Wu Z., Strohl K.P. Brain orexins and wake regulation in rats exposed to maternal deprivation. Brain Res. 2007, 1154:163-172.
17. Geracioti T.D., Baker D.G., Ekhator N.N., West S.A., Hill K.K., Bruce A.B., Schmidt D., et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am. J. Psychiatry 2001, 158:1227-1230.
18. Geracioti T.D., Baker D.G., Kasckow J.W., Strawn J.R., Mulchahey J., Dashevsky B.A., Horn P.S., Ekhator N.N. Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorder. Psychoneuroendocrinology 2008, 33:416-424.
19. Geracioti T.D., Strawn J.R., Ekhator N.N., Wortman M., Kasckow J.W. Neuroregulatory peptides of central nervous system origin: from laboratory to clinic. Hormones, Brain and Behavior 2009, Academic Press, San Diego, CA. 2nd ed. Pfaff, Arnold, Etgen, Fahrbach, Moss, Rubin (Eds.).
20. Griffond B., Risold P.Y., Jacquemard C., Colard C., Fellmann D. Insulin-induced hypoglycemia increases preprohypocretin (orexin) mRNA in the rat lateral hypothalamic area. Neurosci. Lett. 1999, 262:77-80.
21. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1962, 23:56-62.
22. Hill K.K., West S.A., Ekhator N.N., Bruce A.B., Wortman M.D., Baker D.G., Geracioti T.D. The effect of lumbar puncture stress on dopamine and serotonin metabolites in human cerebrospinal fluid. Neurosci. Lett. 1999, 276:25-28.
23. Ida T., Nakahara K., Murakami T., Hanada R., Nakazato M., Murakami N. Possible involvement or orexin in the stress reaction in rats. Biochem. Biophys. Res. Commun. 2000, 270:318-323.
24. Kastin A.J., Akerstrom V. Orexin-A but not orexin B rapidly enters brain from blood by simple diffusion. J. Pharmacol. Exp. Ther. 1999, 289:219-223.
25. Korotkova T.M., Brown R.E., Sergeeva O.A., Ponomarenko A.A., Haas H.L. Effects of arousal- and feeding-related neuropeptides on dopaminergic and GABAergic neurons in the ventral tegmental area of the rat. Eur. J. Neurosci. 2006, 23:2677-2685.
26. Mazzocchi G., Malendowicz L.K., Gottardo L., Aragona F., Nussdorfer G.G. Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. J. Clin. Endocrinol. Metab. 2001, 86:778-782.
27. Meewisse M.L., Reitsma J.B., de Vries G.J., Gersons B.P., Olff M. Cortisol and post-traumatic stress disorder in adults: systematic review and meta-analysis. Br. J. Psychiatry 2007, 191:387-392.
28. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., Vankova J., Black J., Harsh J., Bassetti C., Schrader H., Nishino S. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol. 2002, 59:1553-1562.
29. Muschamp J.W., Dominguez J.M., Sato S.M., Shen R.Y., Hull E.M. A role for hypocretin (orexin) in male sexual behavior. J. Neurosci. 2007, 27:2837-2845. 2007.
30. Nishino S., Ripley B., Mignot E., Benson K.L., Zarcone V.P. CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res. 2002, 110:1-7.
31. Nishino S. The hypothalamic peptidergic system, hypocretin/orexin and vigilance control. Neuropeptides 2007, 41:117-133.
32. Peyron C., Tighe D.K., van den Pol A.N., de Lecea L., Heller H.C., Sutcliffe J.G., Kilduff T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 1998, 18:9996-10015.
33. Porstmann T., Kiessig S.T. Enzyme immunoassay techniques. An overview. J. Immunol. Methods 1992, 150:5-21.
34. Ripley B., Overeem S., Fujiki N., Nevsimalova S., Uchino M., Yesavage J., Di Monte D., Dohi K., Melberg A., Lammers G.J., Nishida Y., Roelandse F.W., Hungs M., Mignot E., Nishino S. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253-2258.
35. Salomon R.M., Ripley B., Kennedy J.S., Johnson B., Schmidt D., Zeitzer J.M., Nishino S., Mignot E. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol. Psychiatry 2003, 54:96-104.
36. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S., Arch J.R., Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E., Liu W.S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
37. Sarchielli P., Rainero I., Coppola F., Rossi C., Mancini M., Pinessi L., Calabresi P. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia 2008, 28:714-722.
38. Singareddy R., Uhde T., Commissaris R. Differential effects of hypocretins on noise-alone versus potentiated startle responses. Physiol. Behav. 2006, 89:650-655.
39. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1987, 150:279.
40. Southwick S.M., Krystal J.H., Bremner J.D., Morgan C.A., Nicolaou A.L., Nagy L.M., Johnson D.R., Heninger G.R., Charney D.S. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch. Gen. Psychiatry 1997, 54:749-758.
41. Strawn J.R., Ekhator N.N., Geracioti T.D. In-use stability of monoamine metabolites in human cerebrospinal fluid. J. Chromatogr. B 2001, 760:301-306.
42. Strawn J.R., Geracioti T.D. Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depress. Anxiety 2008, 25:260-271.
43. Suzuki M., Beuckmann C.T., Shikata K., Ogura H., Sawai T. Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Brain Res. 2005, 1044:116-121.
44. Tao R., Ma Z., McKenna J.T., Thakkar M.M., Winston S., Strecker R.E., McCarley R.W. Differential effect of orexins (hypocretins) on serotonin release in the dorsal and median raphe nuclei of freely behaving rats. Neuroscience 2006, 141:1101-1105.
45. Wheler G.H., Brandon D., Clemons A., Riley C., Kendall J., Loriaux D.L., Kinzie J.D. Cortisol production rate in posttraumatic stress disorder. J. Clin. Endocrinol. Metab. 2006, 91:3486-3489.
46. Yehuda R. Neuroendocrine aspects of PTSD. Handbook Exp. Pharmacol. 2005, 169:371-403.
47. Zhu L., Onaka T., Sakurai T., Yada T. Activation of orexin neurones after noxious but not conditioned fear stimuli in rats. Neuroreport 2002, 13:1351-1353.